Introduction
============

Considerable progress in the understanding of coronary heart disease (CHD) risk factors has been made in the past decades, leading to the development of strategies to reduce CHD event rate. The ability of HMG-CoA reductase inhibitors (statins) to reduce the occurrence of CHD in individuals with hypercholesterolaemia has been reported in large primary and secondary prevention trials. Intervention trials using statins to lower low-density lipoprotein cholesterol (LDL-C) have consistently shown substantial reductions in major cardiovascular events in the treated groups ([@b50]; [@b43]; [@b15]; [@b49]; [@b1]), that was shown to be a function of the extent of LDL-C lowering ([@b1]). However, risk reduction with statin therapy is limited to about 30%, and the ability to adequately identify individuals at high risk for the development of CHD by total or LDL-C levels is limited by the fact that almost 50% of CHD patients have serum cholesterol levels in the normal range ([@b22]). Thus, additional factors appear to modulate the risk of CHD independently LDL-C level.

Early data had shown that low high-density lipoprotein cholesterol (HDL-C) levels are inversely related to CHD incidence in both men and women ([@b63]; [@b25]). It has also been demonstrated that the risk associated with HDL-C is independent of LDL-C levels (Castelli et al 1987). Furthermore, a recent post hoc analysis from the Treating to New Targets (TNT) study ([@b2]), has shown that HDL-C levels are predictive of major cardiovascular events even in patients who maintain LDL-C levels below 70 mg/dL while on statin therapy. In the majority of patients with low HDL-C who develop CHD, this lipoprotein alteration is most often accompanied by elevated triglyceride levels ([@b35]; [@b30]; [@b26]). This raised triglycerides-low HDL-cholesterol dyslipidemic state is a common feature of the altered risk profile of patients with type 2 diabetes, and is largely the consequence of an insulin-resistant state found in viscerally obese patients with the metabolic syndrome ([@b29]; [@b33]; [@b5]). Thus, even in the absence of hyperglycemia or of type 2 diabetes, overweight/obese patients with the features of the metabolic syndrome and the raised triglycerides-low HDL-cholesterol dyslipidemic state have a substantially increased risk of CHD, despite LDL-C levels that are presumably within the 'normal' range ([@b34]). Such dyslipidemia is also characterized by increased levels of atherogenic lipoproteins including, elevated apo B, and small, dense LDL and HDL particles ([@b53]).

It had been known for decades that treatment with fibrates results in substantial decreases in triglyceride levels associated with a moderate increase in HDL-C levels and usually a small reduction in LDL-C levels. This class of drugs has been particularly useful in patients with primary hypertriglyceridemia, mixed hyperlipidemia, and in patients with type 2 diabetes with the raised triglycerides-low HDL-C dyslipidemia ([@b21]). In recent years, significant progress has been made in understanding the mode of action of fibrates. These data have shown that fibrates activate specific transcription factors belonging to the nuclear hormone receptor superfamily, termed peroxisome proliferator-activated receptors (PPAR). Activation of these receptors alters the transcription rate of target genes which play a key role in the development of atherosclerosis. Recent data from the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (\[VA-HIT\] [@b41]), and subgroup analyses from the Bezafibrate Infarction Prevention trial (\[BIP\] [@b57]) have demonstrated that fibrate therapy improves both insulin sensitivity and the blood lipid profile, and significantly attenuates the risk of long-term major cardiovascular events ([@b55]; [@b23]; [@b24]). In this review, the pharmacology of the fibrates is discussed, together with data from recent clinical trials that indicate the potential of the fibrates in general, and bezafibrate specifically, in managing dyslipidemia, with a focus on the use of these drugs in the atherogenic dyslipidemia commonly observed in obese, insulin-resistant and diabetic individuals.

Mechanism of action
===================

Fibrates act as synthetic ligands for PPARα, which are mainly located in the liver, skeletal muscle, heart muscle, and cells in the arterial wall that play a key role in the development of atherosclerosis ([@b61]; Tennenbaum et al 2003; [@b3]). PPAR bind as heterodimers with another nuclear receptor, the retinoid X receptor, to specific response elements termed peroxisome proliferator response elements and alter the transcription rate of target genes. A summary of PPARα-mediated gene regulation by fibrates is provided in [Table 1](#tbl1){ref-type="table"}.

###### 

PPARα-mediated gene regulation by fibrates

  Target gene                      Function of gene product                                 Gene expression
  -------------------------------- -------------------------------------------------------- -----------------
  **Lipoprotein lipase**           Lipolysis, clearance of triglyceride-rich lipoproteins   Increase
  **Apolipoprotein CIII**          Inhibits VLDL clearance                                  Decrease
  **Apolipoprotein AI**            HDL-C formation, reverse cholesterol transport           Increase
  **Apolipoprotein AII**           HDL-C formation, reverse cholesterol transport           Increase
  **Acyl CoA synthetase**          Fatty acid activation, acyl CoA esters                   Increase
  **ABCA1**                        HDL-C formation, cellular cholesterol efflux             Increase
  **Fatty acid binding protein**   Cellular fatty acid uptake                               Increase
  **b-oxidation pathway**          Fatty acid oxidation                                     Increase
  **Acetyl CoA carboxylase**       Fatty acid synthesis                                     Decrease
  **Fibrinogen**                   Blood clotting                                           Decrease
  **C-reactive protein**           Acute phase reactant                                     Decrease
  **Interleukin 6**                Acute phase reactant                                     Decrease
  **Cyclooxygenase-2**             Fatty acid metabolism                                    Decrease
  **VCAM-1**                       Adhesion molecule                                        Decrease

**Abbreviations:** ABCA, ATP binding cassette transporter A1; VCAM-1, vascular cell adhesion molecule-1.

Effect on plasma lipids and lipoproteins
----------------------------------------

Fibrates reduce plasma levels of triglycerides by 30%--50% and typically increase levels of HDL-C by 5%--15%, depending on lipid phenotype and baseline concentration. Fibrates may also reduce LDL-C by up to 15%--20% although the effect is variable, depending on the underlying lipid abnormality and baseline lipid phenotype ([@b11]). Recent investigations have revealed that the lipid effects of fibrates are mediated, at least partly, through the transcription of genes encoding for proteins that control lipoprotein metabolism ([Figure 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). Activation of PPARα results in increased lipolysis and plasma clearance of atherogenic triglyceride-rich lipoproteins via the activation of lipoprotein lipase and ApoAV and reduced production of the lipoprotein lipase inhibitor ApoCIII ([@b28]; Staels et al 1995a; Stael et al 1998; [@b11]). Fibrate therapy also promotes the β-oxidation of fatty acids, thus reducing the availability of free fatty acids for triglyceride synthesis (Schoonjans et al 1996). In addition, de novo fatty acid synthesis is inhibited through reductions in acetyl-CoA carboxylase and fatty acid synthase activity; thereby reducing the availability of fatty acids for triglyceride synthesis ([@b44]; [@b45]).

![Mechanism of action of fibrates.\
**Abbreviations:** HDL, high-density lipoprotein; LDL, low-density lipoprotein; PPAEα, peroxisome proliferator-activated receptor-α; PPRE, peroxisome proliferator response elements; RXR, retinoid X receptor; ↑ indicates increase; ↓ indicates decrease.](vhrm0401-131-01){#fig1}

PPARα activation also increases ApoAI and ApoAII synthesis (the major proteins in HDL) ([@b44]; [@b45]). Cholesteryl ester transfer protein (CETP) activity was found to be reduced with fibrate therapy ([@b31]); and the reduction in CETP-mediated transfer of lipid from HDL-C to very (V) LDL may also contribute to the observed increase in HDL-C levels.

Effects on LDL and HDL particle subclasses
------------------------------------------

Evidence suggests that LDL particle subclasses may differ in atherogenicity, with small, dense LDL associated with greater CHD risk than large, buoyant LDL. The larger particles have a high binding affinity for cellular LDL receptors, and are less susceptible to oxidation. Individuals with the metabolic syndrome and the raised triglycerides-low HDL-C dyslipidemia characteristically have LDL particles that are smaller and contain less cholesterol than average ([@b4]). As a result, the number of atherogenic LDL particles is frequently elevated in this population, even though LDL-C levels are not. Cardiovascular risk was found to be better explained by concentrations of LDL particles or plasma levels of apolipoprotein B (ApoB), than by LDL-C ([@b4]; [@b6]; [@b39]). Fibrate therapy was shown to alter LDL subclass distribution among normolipemic subjects with predominantly dense LDL-C ([@b52]), resulting in a reduction in small dense LDL and an opposite effect on HDL subclass distribution ([@b27]). In a substudy of VA-HIT (Otvos et al 2006), treatment with gemfibrozil was associated with an increase LDL size and a reduction in the number of LDL particles by 5%, while raising the number of HDL particles by approximately 10% and of small HDL subclass particles by 21%. Furthermore, concentrations of these LDL and HDL particles achieved with gemfibrozil were shown to be significant, independent, predictors of major cardiac events and helped explain the demonstrated benefit of fibrate therapy in this population. Other studies have shown that treatment with fenofibrate, ciprofibrate, bezafibrate also exert a beneficial effect on LDL subclass distribution. Notably, among the different agents, fenofibrate has been found to be particularly effective in modulating LDL size and subclasses ([@b39]).

Non-lipid effects
-----------------

Fibrates were shown to exert pleiotropic effects in the artery wall. PPARα is involved in the control of the anti-inflammatory response, via inhibition of the transcription factor NFκB (Chapman 2003), and to attenuate the production of pro-inflammatory stimuli such as interleukin 6 and various prostaglandins, as well as the acute phase proteins, including fibrinogen and C-reactive protein ([@b16]; [@b51]).

Fibrates have favorable effects on coagulation and fibrinolysis. Bezafibrate was shown to reduce levels of fibrinogen by up to 20% ([@b46]), and ciprofibrate and fenofibrate have been shown to increase fibrinolysis and attenuate platelet hyperaggregability in hypercholesterolemic subjects (Simpson et al 1998).

Adverse effects and precautions
===============================

Common adverse reactions of fibrate therapy include gastrointestinal (epigastric distress, flatulence, nausea, diarrhea, constipation) and dermatologic (pruritus, urticaria, or erythema) symptoms, whereas reactions related to the musculoskeletal (muscular weakness, pain, and muscle cramps) and neurological (headache, dizziness) systems are less common. Several specific precautions are listed below.

Hematologic changes
-------------------

Mild hemoglobin, leukocyte and platelet decreases have occurred occasionally following initiation of bezafibrate therapy. However, these levels stabilize during long-term administration. Periodic blood counts are recommended during the first 12 months of administration.

Liver function
--------------

Abnormal liver function tests have been observed occasionally during fibrate administration, including elevated transaminases, and decreased or, rarely, increased alkaline phosphatase. However, these abnormalities are reversible upon discontinuation of the drug. Therefore, periodic liver function tests (AST, ALT, and GGT \[if originally elevated\]) in addition to other baseline tests are recommended after 3--6 months and at least yearly thereafter. Fibrate therapy should be terminated if drug-related abnormalities persist.

Cholelithiasis
--------------

Fibrates may increase cholesterol excretion into the bile, and may lead to cholelithiasis. If such is suspected, gallbladder studies are indicated. Fibrate therapy should be discontinued if gallstones are found.

Hepatobiliary disease
---------------------

In patients with a past history of jaundice or hepatic disorder, fibrates should be used with caution.

Skeletal muscle
---------------

Treatment with drugs of the fibrate class has been associated on rare occasions with myositis or rhabdomyolysis, usually in patients with impaired renal function. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness/weakness, or marked elevations in creatinine phosphokinase (CPK) levels. Patients should be advised to report unexplained muscle pain, tenderness or weakness promptly, particularly if accompanied by malaise or fever. Levels of CPK should be assessed in patients reporting these symptoms, and fibrate therapy should be discontinued if markedly elevated CPK levels (10 times the upper limit of normal) occur or myopathy is diagnosed.

Children
--------

Limited experience is available in children. Therefore, in the absence of adequate information concerning the long-term safety, fibrates should be used with caution in treating this population.

Pregnancy and lactation
-----------------------

Strict birth control procedures must be exercised by women of childbearing potential. If pregnancy occurs despite birth control procedures, fibrate therapy should be discontinued. Women planning a pregnancy should discontinue fibrate therapy several months prior to conception. In the absence of data concerning the presence of fibrates in human breast milk, the drugs should not be used by nursing mothers.

Clinical trials
===============

Fibrates have been in clinical use for over 30 years. Clofibrate was introduced in the 1970s and was followed by gemfibrozil, bezafibrate, fenofibrate and ciprofibrate. Although there have been fewer intervention studies with fibrates than with statins, the majority of available evidence indicate long-term beneficial effects in high-risk patients with the triglyceride-low HDL-C dyslipidemia of the metabolic syndrome, both in primary and secondary intervention settings. A summary of data from major randomized trials of fibrate therapy is provided in [Table 2](#tbl2){ref-type="table"}.

###### 

Summary of major randomized intervention trials involving fibrate therapy

  Trial                               Drug          No. of patients   Baseline lipids mg/dL   End point   Outcome                                    
  ----------------------------------- ------------- ----------------- ----------------------- ----------- --------- -------------------------------- ---------------------------
  **Primary prevention**                                                                                                                             
  WHO                                 Clofibrate    10627             248                     NR          NR        Nonfatal MI                      25% reduction (p \< 0.05)
  Helsinki Heart Study                Gemfibrozil   4081              270                     176         47        Nonfatal MI/CHD death            34% reduction (p \< 0.05)
  **Secondary prevention**                                                                                                                           
  Newcastle                           Clofibrate    497               246                     NR          NR        Fatal/nonfatal MI                14% reduction (p \> 0.10)
  Edinburgh                           Clofibrate    717               265                     NR          NR        CHD events                       53% reduction (p \< 0.05)
  CDP                                 Clofibrate    3892              250                     NR          NR        Nonfatal MI/CHD death            8% reduction (p \> 0.10)
  Stockholm Ischaemic Heart Disease   Clofibrate    555               249                     209         48        Total death                      26% reduction (p \< 0.05)
  VA-HIT                              Gemfibrozil   2531              175                     161         32        Nonfatal MI/CHD death            22% reduction (p \< 0.05)
  BIP                                 Bezafibrate   3090              212                     145         35        Fatal/nonfatal MI/sudden death   9% reduction (p \> 0.10)
  Leader                              Bezafibrate   1568              216                     189         43        Nonfatal MI/CHD death/stroke     4% reduction (p \> 0.10)
  **Primary/secondary prevention**                                                                                                                   
  FIELD                               Fenofibrate   2795              195                     119         42        Nonfatal MI/CHD death            11% reduction (p \> 0.10)

**Notes:** See text for abbreviations of study names.

**Abbreviations:** CHD, coronary heart disease; MI, myocardial infarction; NR, not reported.

Primary prevention
------------------

Clofibrate and gemfibrozil have been investigated in a primary prevention setting in the general population ([Table 2](#tbl2){ref-type="table"}). In the WHO Clofibrate Study ([@b13]), 10,627 men without CHD treated with clofibrate for 5 years showed a 25% reduction in myocardial infarction (MI) and a 20% reduction in first major coronary event. These beneficial results were, however, overshadowed by the reported increase in mortality from non-cardiovascular disease, particularly cancer ([@b13]), although subsequent follow-up showed a smaller difference in cancer incidence between the clofibrate and control groups ([@b13]).

The Helsinki Heart Study (Frick et al 1987) was a placebo-controlled study, including more than 4,000 men at moderate risk of CHD with a range of lipid patterns, but generally with an elevated LDL-C level. The study showed that treatment with gemfibrozil (1,200 mg/day), resulted in an 11% decrease in LDL-C, a 35% decrease in triglycerides and an 11% increase in HDL-C, compared with placebo. These lipid changes were associated with a 34% reduction in major coronary events at five years (p \< 0.02), as well as a 37% reduction in non-fatal MI (p \< 0.05). No significant difference in overall mortality was observed between the two groups.

Secondary prevention
--------------------

The value of fibrate therapy in the secondary prevention setting is supported by numerous studies ([Table 2](#tbl2){ref-type="table"}). Two small trials of clofibrate therapy, Newcastle ([@b59]) and Edinburgh (Trial of clofibrate in the treatment of ischemic heart disease), failed to find a significant reduction in CHD deaths, but did find that clofibrate prevented nonfatal-MI to a variable extent. The Coronary Drug Project (CDP) ([@b12]) was a larger secondary prevention trial that showed a non-significant reduction in CHD events with clofibrate therapy. However, a late lipid-lowering therapy effect was observed in an extended follow-up of the trial ([@b8]), nine years after termination of the trial. The authors attributed this to the transformation of an early favorable effect of niacin in decreasing nonfatal reinfarction, into a mortality benefit over subsequent years. In the Stockholm Ischaemic Heart Disease Secondary Prevention Study ([@b9]), combination treatment with clofibrate (2 g/day) and nicotinic acid (3 g/day) was investigated in 555 post-MI patients (279 received active treatment). Compared with a control group, active treatment reduced triglycerides by 19% and significantly reduced total and CHD mortality by 26% (p \< 0.05) and 36% (p \< 0.01), respectively. Notably, CHD risk reduction was only evident in patients with triglyceride levels higher than the median value at baseline; subjects in whom triglyceride levels were reduced by more than 30% (over 40% of treated patients) experienced a 60% reduction in CHD mortality (p \< 0.01). Subsequently, VA-HIT ([@b41]), involving 2,531 men with established CHD, acceptable LDL-C levels, low HDL-C, and elevated triglycerides ([Table 2](#tbl2){ref-type="table"}), showed that treatment with gemfibrozil produced a significant 22% reduction in the risk of the primary end point of CHD death or non-fatal MI, as well as CHD mortality. It is noteworthy that 25% of patients enrolled in VA-HIT had diagnosed diabetes and over 50% of patients had features of the metabolic syndrome. The BIP study ([@b57]; also described separately in the following section) comprised 3090 patients allocated to bezafibrate (400 mg/day) or placebo. A significant reduction in plasma triglyceride levels and an increase in HDL-C were observed in this study although there was no significant difference in the five-year coronary event rate compared with placebo (9.4% reduction, p = 0.26). However, bezafibrate was shown to be particularly beneficial among patients with elevated triglycerides (\>200 mg/dL) at baseline, in whom a 40% reduction in coronary risk at five years was observed. The Lower Extremity Arterial Disease Event Reduction (LEADER) trial ([@b36]) enrolled 1568 elderly men with lower extremity arterial disease, and showed that bezafibrate (400 mg/day) produced a 40% reduction in non-fatal coronary events (p = 0.05), although there was no significant reduction in the combined end point of CHD and stroke.

Angiographic studies have demonstrated the beneficial effect of fibrate therapy on atherosclerosis progression. The Bezafibrate Coronary Atherosclerosis Intervention Trial (\[BECAIT\] [@b19]), was a relatively small trial designed to evaluate the effects of treatment with bezafibrate on angiographic disease in 92 young male MI survivors. The study showed a significant reduction in the progression of coronary atherosclerosis, as assessed by the change in minimum lumen diameter, in patients treated with bezafibrate compared with placebo. In the Lopid Coronary Angiography Trial ([@b20]), 395 men with low HDL-C and LDL-C levels who had previously undergone CABG, were treated with gemfibrozil (1200 mg/day). The study medication was associated with significantly decreased progression of coronary artery disease in native coronary segments compared with placebo.

Type 2 diabetes
---------------

The pharmacological profile of the fibrates, described above, suggests that these agents may prove useful in correcting the atherogenic dyslipidemia typically associated with type 2 diabetes and the metabolic syndrome.

Subgroup analyses of data from the Helsinki Heart Study ([@b32]) and VA-HIT ([@b42]) showed that among patients with type 2 diabetes, treatment with gemfibrozil was associated with a significant reduction in the risk of coronary events that ranged from 68% ([@b32]) in the primary intervention setting to 32% ([@b42]) in the secondary prevention setting. In the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Prevention (SENDCAP) study ([@b18]), 164 type 2 diabetes patients without a history of CHD, treated with bezafibrate (400 mg/day) for three years, had a lower CHD event rate compared with placebo (7% vs. 23%, p = 0.01). There was, however, no difference between the groups in progression of carotid and femoral artery atherosclerosis, as assessed by changes in intima-media thickness.

More recently, the Diabetes Atherosclerosis Intervention Study (\[DAIS\] [@b60]), involving 418 patients with type 2 diabetes has provided clear evidence of the value of fibrate therapy in diabetic patients. Treatment with micronised fenofibrate, at a dose of 200 mg/day for at least 3 years, was associated with a 40% reduction in angiographic progression of coronary artery disease, as well as a 23% reduction in the cardiovascular event rate, compared with placebo. These beneficial effects were associated with reduction in the levels of triglycerides (by 29%) and LDL-C (by 5%), and an increase in HDL-C (by 7%) and LDL particle size ([@b60]).

The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study ([@b58]) evaluated the role of fibrate therapy in preventing cardiovascular events in patients with type 2 diabetes, considered at increased risk for CHD. After a mean follow-up of 5 years, therapy with fenofibrate was associated wuth a non-significant 11% reduction in the primary end point of nonfatal MI or CHD death. However, total cardiovascular events, corresponding to the secondary end point, were significantly reduced with fenofibrate by 11% (p = 0.035), mainly due to significant reductions in non-fatal MI (by 24%, p = 0.01) and coronary revascularization (by 21%, p = 0.003). Treatment effects were larger in patients without cardiovascular disease than in those with a history of cardiovascular disease. Notably, end points that concerned microangiographic manifestations of diabetes were significantly improved by fenofibrate treatment; these included a reduction in the need for laser treatment for retinopathy and reduction in the progression of albuminuria.

Bezafibrate therapy: recent data from the BIP trial
===================================================

Bezafibrate was the first clinically tested pan -- (alpha, beta/delta, gamma) PPAR activator (Peters et al 2000; [@b57]; Cobrero et al 2001; [@b38]; [@b62]), and is a sole pan PPAR activator with more than a quarter of a century of a therapeutic experience with a good safety profile. The BIP study was designed to determine whether bezafibrate would reduce CHD mortality and nonfatal MI in CHD patients with low HDL-C and LDL-C in a moderate range ([@b57]). The study demonstrated fewer cardiac events with bezafibrate (13.6%) as compared with placebo (15.0%) during a 6.2-year mean follow-up period. However, event rate was not significantly reduced (p = 0.26) despite reductions of 5% in LDL-C, 16% in triglyceride, and 10% in fibrinogen levels, together with an increase of 14% in HDL-C levels compared with placebo. A post hoc analysis in patients with high baseline triglycerides (200 mg/dL) revealed that the reduction in the cumulative probability of the primary end point by bezafibrate was 39.5% (p = 0.02) in that subgroup.

There are several explanations for the differences in outcome between VA-HIT and BIP in addition to the difference in the type of fibrate drug. First, LDL-C levels in BIP were in a moderately high range at baseline (averaging 149 mg/dL), necessitating a relatively large prescription rate of "off-trial" lipid lowering therapies, mainly in the placebo group (15% of placebo-allocated patients received active lipid therapy by the end of the study), thereby attenuating the margin of difference in outcome between the placebo and active treatment groups. Second, differences in patient characteristics might have affected outcome in the 2 trials: BIP excluded individuals with diabetes and higher levels of blood glucose as well as recruited fewer individuals with components of the metabolic syndrome, in whom the efficacy of fibrate therapy is enhanced, resulting in a lower event rate during follow-up. Despite these differences in trial design, recent subgroup analyses from BIP revealed several important findings regarding the long-term cardiovascular effects of bezafibrate that are described below.

Relationship between on-treatment increments in serum HDL-cholesterol levels and cardiac mortality
--------------------------------------------------------------------------------------------------

In a subanalysis of BIP we evaluated the relationship between changes in serum levels of HDL-C under bezafibrate therapy and cardiac mortality in enrolled subjects ([@b23]). Long-term follow-up revealed that cardiac mortality was significantly reduced with increasing increments of on-treatment HDL-C change (9.5%, 6.6%, and 6.3% of patients died of cardiac causes in tertiles 1, 2, and 3 of HDL-C increase, respectively \[p for trend = 0.02\]); [Figure 2](#fig2){ref-type="fig"}). The magnitude of on-treatment HDL-C increment in the trial was shown to be independently associated with reduced risk of cardiac death: patients who did not respond to bezafibrate therapy by increasing serum HDL-C levels (tertile 1 HDL-C change) did not experience a survival benefit with bezafibrate therapy (hazard ratio: 1.05 \[95% CI 0.74--1.47\]), whereas responders (tertile 3 HDL-C increase) experienced a significant 35% reduction in the risk of cardiac death with bezafibrate (HR = 0.65 \[95% CI 0.43--0.97\]). Furthermore, the risk of cardiac mortality was reduced by 27% for every 5 mg/dL increase in on-treatment HDL-C change (p \< 0.001). Thus, these findings demonstrate an independent association between a rise in HDL-C with bezafibrate therapy and a reduction in cardiac mortality, and suggest that monitoring short-term response to bezafibrate therapy through HDL-C change may indicate the potential long-term benefit of the drug.

![All-cause and cardiac mortality rates in tertiles of HDL-C change in the bezafibrate group compared to the placebo group.\
\*p for trend \< 0.05\
Reprinted with permission from [@b23].](vhrm0401-131-02){#fig2}

Long-term cardioprotective effects of bezafibrate therapy
---------------------------------------------------------

We have recently completed an evaluation of the effect of bezafibrate therapy over an extended follow-up period of BIP ([@b24]). After discontinuation of study medication, patients were observed for coronary events for an additional period, bringing the total follow-up time in the current analysis to a mean of 8.2 years (median: 7.9 years; interquartile range: 7.2--8.7 years). Our data demonstrate that during long-term follow-up bezafibrate therapy was associated with a significant 17% reduction (p = 0.03) in the combined end point of cardiac death or nonfatal MI ([Figure 3](#fig3){ref-type="fig"}). Using interaction-term analysis, we have also shown that the benefit of bezafibrate therapy was pronounced (18% risk reduction; p = 0.03) without- or before- treatment with off-trial lipid lowering therapies was initiated during follow-up, and attenuated (HR = 1.05; p = 0.85) after therapy with off-trial lipid lowering therapies was initiated during the observation period. These new data suggest that bezafibrate therapy is associated with significant long-term cardiovascular protection that may extend beyond the period of active drug therapy.

![Kaplan-Meier cumulative probability of outcome the combined endpoint of cardiac death or nonfatal myocardial infarction, and cardiac death separately, during an extended follow-up of the BIP trial.\
\*p \< 0.05.](vhrm0401-131-03){#fig3}

Effect of bezafibrate therapy in patients with the metabolic syndrome
---------------------------------------------------------------------

A post hoc analysis of BIP evaluated the effect of bezafibrate on the incidence of MI during long-term follow-up in enrolled patients with metabolic syndrome ([@b55]). Patients who displayed at least 3 of the following 5 risk factors were considered to have metabolic syndrome: (1) a fasting glucose level of 110 mg/dL (6.11 mmol/L); (2) a triglyceride level of 150 mg/dL (1.70 mmol/L); (3) HDL-C level less than 40 mg/dL in men or less than 50 mg/dL in women; (4) a systolic blood pressure of 130 mm Hg or diastolic blood pressure of 85 mm Hg; and (5) a body mass index of 28.0 kg/m^2^. During the course of the extended follow-up period bezafibrate was associated with a significant reduction in the risk of MI, and of the combined primary endpoint of BIP, which consisted of nonfatal MI or sudden cardiac death, among patients with at least 3 risk factors for the metabolic syndrome ([Figure 4](#fig4){ref-type="fig"}). Furthermore, the benefit of bezafibrate therapy was shown to be enhanced in patients with augmented features (at least 4 risk factors) of the metabolic syndrome (56% reduction of cardiac mortality during 8-year follow-up), whereas the benefit of bezafibrate was attenuated in patients without features of the metabolic syndrome.

![Outcome of patients with the metabolic syndrome in BIP.\
\*p \< 0.05.\
**Abbreviation:** MI, myocardial infarction.](vhrm0401-131-04){#fig4}

Bezafibrate therapy for the prevention of type 2 diabetes mellitus in patients with coronary artery disease
-----------------------------------------------------------------------------------------------------------

In a recent study from BIP we evaluated whether pharmacological intervention with bezafibrate that influences primary lipid metabolism can also delay development of type 2 diabetes ([@b56]). The study comprised 303 non-diabetic study patients with a fasting blood glucose level of 110 to 125 mg/dL, who were allocated to either 400 mg bezafibrate (n = 156) or placebo (n = 147 patients) once a day. During follow-up, development of new-onset diabetes occurred at a significantly lower rate among bezafibrate allocated patients as compared with placebo ([Figure 5](#fig5){ref-type="fig"}). The mean time until onset of new diabetes was significantly delayed among the former subgroup as compared with the latter: 4.6 ± 2.3 versus 3.8 ± 2.6 years, respectively, (p = 0.004), and bezafibrate therapy was shown to be associated with a significant 30% reduction in the risk of new diabetes development. These findings suggest that treatment with fibrates may reduce the incidence and delay the onset of type 2 diabetes in patients with impaired fasting glucose, and need to be validated in future prospective studies.

![Two- and five-year Kaplan-Meier cumulative probability of diabetes incidence (in accordance with time of diagnosis after annual fasting blood glucose measurements) in the bezafibrate and placebo groups of the BIP trial.](vhrm0401-131-05){#fig5}

Conclusions and future perspectives
===================================

With the epidemic proportions of obesity, especially high-risk abdominal obesity, type 2 diabetes and the metabolic syndrome, it is important to consider lipid lowering therapies that affect the dyslipidemic profile found in these patients, independently of LDL-C. Data from recent major clinical trials have shown that fibrates produce beneficial effects on atherogenic lipoproteins through activation of PPARα, and confer long-term cardiovascular protection, both in the primary- and secondary- prevention setting. Therefore, this mode of lipid-lowering therapy should be considered part of an optimal management plan in a significant proportion of patients with a high-risk metabolic profile.

Recent data from the BIP trial have demonstrated several important findings regarding the benefit of this fibric acid derivative in CHD patients, including (1) long-term cardioprotective effects that extend beyond the period of active drug therapy; (2) enhanced efficacy in "responders" (patients in whom HDL-C levels increase in response to bezafibrate therapy; (3) enhanced efficacy in patients with elevated triglycerides and those with clinical and laboratory features suggestive of the metabolic syndrome; and (4) a significant reduction in the incidence of new onset of type 2 diabetes in patients with impaired fasting glucose.

Further studies are needed to compare the benefit of statin versus fibrate therapy, or the combination of both classes of drugs, in different subpopulations of patients with a high-risk metabolic profile.
